Бетриксабан (PRT054021)
Открытое нерандомизированное исследование 1 фазы с однократным дозированием по оценке фармакокинетики, фармакодинамики и безопасности применения Бетриксабана у пациентов детского возраста
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/599/2017-11-17/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза I — первое применение у людей. Проверяют безопасность и подбирают дозу, участников немного.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 2–17 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 30 чел. в стране «Россия».
- Центров в реестре: 8 в 6 городах. Список — ниже на странице.
- Плановая дата окончания (12.2019) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 25
Критерии включения
- Pediatric participants in the following age categories: 12 to < 18 years of age and 2 to < 12 years of age. Part 1 of the study enrolled only adolescent participants 12 to < 18 years of age.
- Pediatric participant who was assessed to be at risk for VTE but did not require immediate anticoagulant therapy, for example:
- Had previous thrombosis and completed a course of anti-coagulant therapy, and is considered to have a risk for recurrence of VTE, or
- Had any stable disease with a risk for arterial or venous thromboembolism, or
- Had any functional central venous access device in the upper or lower venous system.
- Participant had normalized coagulation parameters (international normalized ratio or partial thromboplastin time, as appropriate) within 7 days of study drug administration.
Критерии невключения
- Participants who meet any one of the following exclusion criteria were excluded from the study:
- Participant received any dose of anti-coagulant therapy within 7 days of Day 1.
- Participant had active bleeding or had a comorbid disorder that placed the participant at high risk for bleeding.
- Participant had a comorbid disorder that placed the participant at risk of death within 90 days of enrollment.
- Participant had abnormal coagulation tests at baseline.
- Participant had recent or planned invasive procedures, including lumbar puncture and removal of non-peripherally placed central lines during study.
- Participant had hepatic disease associated with one or more of the following:
- Transaminase levels ≥ 2.5 × upper limit of normal (ULN) or bilirubin ≥ 1.5 × ULN at baseline.
- Coagulopathy leading to a clinically relevant bleeding risk, or hepatic transaminase level of > 2 × ULN or total bilirubin > 2 × ULN with direct bilirubin > 20% of the total.
- Platelet count < 75 × 10\^9/liter or hemoglobin < 10.0 mg/deciliter.
- Hypertension.
- Participant had known congenital or acquired bleeding diathesis.
- Participant required concomitant therapy with a strong P-glycoprotein inhibitor.
- Participant had previous history of any non-traumatic bleeding event that was life threatening or required medical attention.
- Participant had been administered thrombolytic therapy, or had undergone thrombectomy, or insertion of a caval filter to treat prior VTE.
- Participant had known inherited or acquired bleeding diathesis or coagulopathy.
- Participant had abnormal QTcF interval on baseline electrocardiogram.
- Participant received a dose of any antiplatelet medication (including aspirin) within 14 days before study drug dosing.
- Participant had malabsorption disorders (for example, cystic fibrosis or short bowel syndrome).
- Participant had an estimated glomerular filtration rate < 30 milliliters/minute.
- Participant was unable or reluctant to cooperate with the study procedures.
- Participant had hypersensitivity to other Factor Xa inhibitors, or the components of the dosage form.
- Participant had participated in a study with an investigational drug or medical device within 30 days prior to administration of betrixaban.
- Participant was female and of childbearing potential and was either pregnant or breastfeeding a child.
- Participant was sexually active and was not using medically accepted contraceptive method (if applicable).
Источник: ClinicalTrials.gov, NCT03346083 · запись обновлена в реестре 12 января 2024.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 7
- Area Under The Plasma Concentration-Time Curve From 0 To Infinity (AUC(0-inf)) Of Betrixaban — Up to 6 days post dose
- Maximum Observed Plasma Concentration (Cmax) Of Betrixaban — Up to 6 days post dose
Цель исследования
This trial was a Phase 1, open-label, multicenter study of the pharmacokinetics (PK), pharmacodynamics (PD), and safety of a single dose of betrixaban in pediatric participants at risk of venous thromboembolism (VTE).
Области и заболевания
Где проходит
8 центров в 6 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 599 от 17.11.2017 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03346083 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
clinmarket · № 1891 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.